Latest Cervarix Stories
Expansion Comes After Successful Phase II Trial for Cervical Dysplasia PLYMOUTH MEETING, Pa., Sept. 22, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
KIGALI, Rwanda, Aug. 27, 2014 /PRNewswire-USNewswire/ -- Seraphine Mukandutiye, 50, is a Rwandan woman with a beautiful and glowing smile.
LA JOLLA, Cali., Aug. 22, 2014 /PRNewswire/ -- Research presented at the 29(th) Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc.
A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix. Women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine were followed for more than nine years, and vaccine efficacy (VE) against incident infection was 100%.
Inovio Responds to False and Misleading Speculation Regarding Immunotherapy Study BLUE BELL, Pa., June 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Teenage girls who practice risky sex have higher rates of HPV and herpes than those in the general population according to a study reported on Healio.com on May 20, 2014 (1).
ST. PAUL, Minn., Feb.
Report Outlines Recommendations to Overcome Barriers and Support Cancer Prevention Efforts WASHINGTON, Feb.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.